Adia Med, Inc. (ADIA) income statement
ADIAOTCMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
$0.13−0.01 (-7.14%)
Close on Oct 19, 2026Market cap $20.98MP/E –Yield –
Adia Med, Inc. financial ratios
See a number that looks wrong?
Close on Oct 19, 2026Market cap $20.98MP/E –Yield –
See a number that looks wrong?
| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Margins | |||
| Gross margin | 27.4% | 34.4% | – |
| Operating margin | -52.3% | -2,739.0% | – |
| EBITDA margin | -51.7% | -2,732.2% | – |
| Pre-tax margin | -56.5% | -2,838.0% | – |
| Net profit margin | -56.5% | -2,838.0% | – |
| Free cash flow margin | -27.5% | -5,600.4% | – |
| Returns on capital | |||
| Return on equity | 340.7% | -1,460.8% | – |
| Return on assets | -62.7% | -27.2% | – |
| Return on tangible assets | -62.7% | -27.4% | – |
| Return on capital employed | -168.2% | -29.8% | – |
| NOPAT | -$289.53K | -$138.05K | – |
| Cash flow quality | |||
| OCF / Sales | -25.6% | -5,258.2% | – |
| OCF / Net income | 0.45 | 1.85 | – |
| FCF / OCF | 107.4% | 106.5% | – |
| FCF / Net income | 0.49 | 1.97 | – |
| FCF / EBITDA | 53.1% | 205.0% | – |
| Unlevered free cash flow | -$167.47K | -$352.32K | – |
| Levered free cash flow | -$192.43K | -$357.31K | – |
| Efficiency | |||
| Asset turnover | 1.11 | 0.01 | – |
| Fixed asset turnover | 26.77 | 0.29 | – |
| Receivables turnover | 42.00 | – | – |
| Days sales outstanding | 8.7 | – | – |
| Payables turnover | 140.00 | 0.86 | – |
| Days payables outstanding | 2.6 | 425.2 | – |
| Inventory turnover | 4.39 | 0.02 | – |
| Days inventory outstanding | 83.2 | 18,039.5 | – |
| Operating cycle | 91.9 | – | – |
| Cash conversion cycle | 89.3 | – | – |
| CapEx to revenue | 1.9% | 342.2% | – |
| CapEx to OCF | -7.4% | -6.5% | – |
| CapEx to depreciation | 3.19 | 50.42 | – |
| Liquidity | |||
| Current ratio | 0.22 | 3.23 | – |
| Quick ratio | 0.18 | 0.64 | – |
| Cash ratio | 0.11 | 0.08 | – |
| Working capital | -$583.69K | $178.40K | – |
| Net current asset value | -$690.99K | -$382.25K | – |
| Leverage | |||
| Assets to equity | -2.31 | 26.08 | – |
| Intangibles to total assets | 0.00% | 0.89% | – |
| Interest coverage | |||
| EBIT / Interest expense | -11.60 | -27.66 | – |
| EBITDA / Interest expense | -11.47 | -27.59 | – |
| (EBITDA − CapEx) / Interest expense | -11.89 | -31.05 | – |
| Per share | |||
| Revenue per share | 0.0075 | 0.0001 | – |
| EPS (basic) | 0.00 | 0.00 | – |
| EPS (diluted) | 0.00 | 0.00 | – |
| Book value per share | -0.0028 | 0.0003 | – |
| Tangible book value per share | -0.0028 | 0.0002 | – |
| Cash per share | 0.0008 | 0.0001 | – |
| Operating cash flow per share | -0.0019 | -0.0037 | – |
| Free cash flow per share | -0.0021 | -0.0039 | – |
| CapEx per share | 0.0001 | 0.0002 | – |
| Valuation at period end | |||
| Market cap | $7.16M | – | – |
| Enterprise value | $7.15M | – | – |
| P/S | 10.2x | – | – |
| P/B | -27.8x | – | – |
| P/TBV | -27.8x | – | – |
| P/Gross profit | 37.3x | – | – |
| P/OCF | -39.9x | – | – |
| EV/Sales | 10.2x | – | – |
| EV/Gross profit | 37.3x | – | – |
| EV/OCF | -39.9x | – | – |
| Earnings yield | -5.5% | – | – |
| FCF yield | -2.7% | – | – |
| Cost structure | |||
| R&D to revenue | 4.2% | 0.00% | – |
| Stock-based comp to revenue | 6.0% | 483.7% | – |
| Per employee | |||
| Total employees | 3 | 3 | 3 |
| Revenue per employee | $233.50K | $2.13K | – |
| Gross profit per employee | $63.89K | $731 | – |
| Operating profit per employee | -$122.16K | -$58.25K | – |
| Net income per employee | -$131.82K | -$60.36K | – |
| Free cash flow per employee | -$64.14K | -$119.10K | – |
| Growth | |||
| Revenue 1Y growth | 10,879.7% | – | – |
| Gross profit 1Y growth | 8,636.1% | – | – |
| EBIT 1Y growth | -109.7% | – | – |
| EBITDA 1Y growth | -107.9% | – | – |
| Net income 1Y growth | -118.4% | – | – |
| Operating cash flow 1Y growth | 46.6% | – | – |
| Free cash flow 1Y growth | 46.1% | – | – |
| CapEx 1Y growth | -39.5% | – | – |
| Total assets 1Y growth | -10.7% | – | – |
| Total equity 1Y growth | -1,108.9% | 3,505.3% | – |
Every figure here is calculated from standardized financial statements — hover a row name for the formula — not reported by the company. Valuation multiples use the closing price at the end of that period, not today's price.